Sugi Predict

Sugi Predict / Compounds / SCHEMBL5240905

SCHEMBL5240905

SCHEMBL5240905

O=c1c(O)c(CNCCCn2ccnc2)ccn1Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VEGFA P15692 7/20 1.00
▸ EGLN1 Q9GZT9 7/20 1.00
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ QPCT Q16769 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.45
▸ HPGD P15428 1/20 0.45
▸ DUSP3 P51452 1/20 0.45
▸ PTPN5 P54829 1/20 0.45
▸ PTPN11 Q06124 1/20 0.45
▸ KMT2A Q03164 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ TSHR P16473 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP19A1 P11511 1/20 0.44
▸ CYP11B1 P15538 1/20 0.44
▸ CYP11B2 P19099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12649393 0.94 EGLN1 (0.88) VEGFAEGLN1SMN1; SMN2QPCTCYP1A2
SCHEMBL15314773 0.86 VEGFA (0.75) VEGFAEGLN1SMN1; SMN2QPCTALDH1A1
SCHEMBL16281892 0.85 VEGFA (0.74) VEGFAEGLN1SMN1; SMN2QPCTKMT2A
SCHEMBL272385 0.79 EGLN1 (0.76) VEGFAEGLN1SMN1; SMN2ALDH1A1
SCHEMBL6917874 0.79 VEGFA (0.65) VEGFAEGLN1SMN1; SMN2QPCTALDH1A1
SCHEMBL12669231 0.79 EGLN1 (0.72) VEGFAEGLN1SMN1; SMN2CYP2D6
SCHEMBL272670 0.78 EGLN1 (0.88) VEGFAEGLN1SMN1; SMN2ALDH1A1POLB
SCHEMBL2475754 0.78 QPCT (0.67) VEGFAEGLN1SMN1; SMN2QPCTKMT2A
SCHEMBL271531 0.77 EGLN1 (0.63) VEGFAEGLN1
SCHEMBL13896549 0.76 VEGFA (0.60) VEGFAEGLN1SMN1; SMN2QPCTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558579-B1 N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS PROCTER & GAMBLE (US) 2007-09-12 — — EP claimed
US-6930117-B2 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2005-08-16 — — US claimed
CN-116018136-A Hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of aging-related disorders 百爱及生物医药公司 2023-04-25 — — CN disclosed
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
EP-3698794-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS Aerpio Therapeutics, Inc. (US) 2020-08-26 — — EP disclosed
US-10562854-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS, INC. (US) 2020-02-18 — — US disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 — — EP disclosed
EP-3603644-A1 PROLYL HYDROXYLASE INHIBITORS Aerpio Therapeutics, Inc. (US) 2020-02-05 — — EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
EP-2952192-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2019-05-15 — — EP disclosed
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2019-02-21 — — US disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed
US-20070270407-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2007-11-22 — — US disclosed
US-20050234045-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2005-10-20 — — US disclosed
US-6930117-B2 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY (US) 2005-08-16 — — US disclosed
EP-1558579-A1 N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS THE PROCTER & GAMBLE COMPANY (US) 2005-08-03 — — EP disclosed
WO-2004043927-A1 N-ALKYL-4-METHYLENEAMINO-3-HYDROXY-2-PYRIDONES AS ANTIMICROBIALS THE PROCTER & GAMBLE COMPANY (US) 2004-05-27 — — WO disclosed
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones THE PROCTER & GAMBLE COMPANY 2004-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097560-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, CYP51A1, CD4 VEGFA 3112/4885EGLN1 926/4885SMN1; SMN2 1321/4885
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS ALPI, SI, SLC10A2 VEGFA 4546/4885EGLN1 2861/4885SMN1; SMN2 3357/4885
US-20070270407-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, IFNG, CD4 VEGFA 2758/4885EGLN1 1060/4885SMN1; SMN2 1629/4885
US-20190055198-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 VEGFA 551/4885EGLN1 5/4885SMN1; SMN2 2791/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 VEGFA 551/4885EGLN1 5/4885SMN1; SMN2 2791/4885
US-20050234045-A1 N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones IL17A, IFNG, CD4 VEGFA 3064/4885EGLN1 1182/4885SMN1; SMN2 1685/4885
US-10562854-B2 Prolyl hydroxylase inhibitors HIF1AN, HIF1A, EGLN2 VEGFA 551/4885EGLN1 5/4885SMN1; SMN2 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.